Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 5/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327212 | 0.91 | CYP11B1 (0.43) | CYP11B1CYP11B2NOTUMALDH1A1HTT | |
| SCHEMBL30003575 | 0.90 | CYP11B1 (0.39) | CYP11B1CYP11B2NOTUMLPLLIPG | |
| SCHEMBL13035958 | 0.90 | CYP11B1 (0.39) | CYP11B1CYP11B2NOTUMLPLLIPG | |
| SCHEMBL17423914 | 0.85 | LPL (0.39) | CYP11B1CYP11B2LPLLIPGIDO1 | |
| SCHEMBL24610257 | 0.82 | LPL (0.39) | LPLLIPGARPTGER3 | |
| SCHEMBL28502429 | 0.81 | PRMT5 (0.38) | NOTUMLPLLIPGARIDO1 | |
| SCHEMBL20206428 | 0.80 | LPL (0.42) | NOTUMLPLLIPGIDO1TDO2 | |
| SCHEMBL30955785 | 0.79 | ALDH1A1 (0.39) | CYP11B1CYP11B2NOTUMALDH1A1HTT | |
| SCHEMBL758834 | 0.78 | USP30 (0.41) | CYP11B1CYP11B2LPLLIPG | |
| SCHEMBL2839072 | 0.78 | AVPR1A (0.32) | LPLLIPGIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478516-B | 3, 4-dihydro-2H-quinolizin-2-one compound and preparation method thereof | 中国科学院成都有机化学有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1858900-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006097691-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885NOTUM 188/4885 |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | CYP11B1 983/4885CYP11B2 1147/4885NOTUM 4500/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | CYP11B1 3922/4885CYP11B2 3817/4885NOTUM 1958/4885 |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | CYP11B1 3819/4885CYP11B2 3441/4885NOTUM 3134/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885NOTUM 188/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | CYP11B1 66/4885CYP11B2 168/4885NOTUM 197/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | CYP11B1 318/4885CYP11B2 379/4885NOTUM 4566/4885 |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | CYP11B1 1294/4885CYP11B2 940/4885NOTUM 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.